Clinical Update

In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections1
Ceftaroline was active against the gram-positive isolates collected. Susceptibility of ESBL-negative gram-negative isolates showed regional variations.1

Ceftaroline achieved PTAs for bacteriostatic and bactericidal targets at the MIC90 (1 mg/L), whereas the comparators failed to achieve PTAs2
Ceftaroline achieved PTAs >99.9% for bacteriostatic and bactericidal targets at the MIC90 (1 mg/L), whereas the comparators failed to achieve PTAs >90% for bacteriostatic or bactericidal targets, even when clinical doses were increased beyond the recommended level(s).2

Exploratory analyses of the Phase 3 COVERS trial: Shorter median treatment duration showed in the ceftaroline fosamil group versus the vancomycin + aztreonam group in patients who were admitted to the ICU3
Ceftaroline fosamil is a beta-lactam antibiotic with in vitro activity against MRSA. The Phase 3 COVERS study demonstrated the efficacy and safety of a high dose regimen of ceftaroline fosamil (600 mg 2 h IV infusions q8h) versus vancomycin plus aztreonam in hospitalised patients with cSSTI and underlying comorbidities.3

Ceftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile4
Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by MDR pathogens. On the basis of analysis, ceftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.4

A real-world two-centre experience in Italy and Spain: Ceftaroline represents an important option for severe CAP5
Ceftaroline is one of the latest additions to the armamentarium for treating CAP. Considering its spectrum of activity, ceftaroline could represent an important therapeutic option for SCAP.5





CAP: community-acquired pneumonia; cSSTI: complicated skin and soft tissue infections; 
ESBL: extended-spectrum beta-lactamases; ICU: intensive care unit; IV: intravenous; 
MDR: multi-drug resistant; MIC: minimum inhibitory concentrations; MRSA: methicillin-resistant Staphylococcus aureus; PTA: probability of target attainment; SCAP: severe community-acquired pneumonia

References:
1. Piérard D, Stone GG. J Glob Antimicrob Resist. 2021;26:4-10.
2. Cristinacce A, Wright JG, Macpherson M, Iaconis J, Das S. Diagn Microbiol Infect Dis. 2021;99(4):115292.
3. Sánchez-García M, Hammond J, Yan JL, Kantecki M, Ansari W, Dryden M. Infect Dis Ther. 2020;9(3):609-623.
4. Sotgiu G, Aliberti S, Gramegna A, et al. Respir Res. 2018;19(1):205.
5. Bassetti M, Russo A, Cilloniz C, et al. Int J Antimicrob Agents. 2020;55(4):105921.
 

PP-ZFO-IND-0279.  09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioner, or a hospital or a laboratory.